RT Journal Article
SR Electronic
T1 Modeling COVID19 mortality in the US: Community context and mobility matter
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.18.20134122
DO 10.1101/2020.06.18.20134122
A1 McGough, Sarah F.
A1 Gan, Ryan W.
A1 Tibshirani, Robert
A1 Meyer, Anne-Marie
YR 2020
UL http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134122.abstract
AB The United States has become an epicenter for the coronavirus disease 2019 (COVID-19) pandemic. However, communities have been unequally affected and evidence is growing that social determinants of health may be exacerbating the pandemic. Furthermore, the impact and timing of social distancing at the community level have yet to be fully explored. We investigated the relative associations between COVID-19 mortality and social distancing, sociodemographic makeup, economic vulnerabilities, and comorbidities in 24 counties surrounding 7 major metropolitan areas in the US using a flexible and robust time series modeling approach. We found that counties with poorer health and less wealth were associated with higher daily mortality rates compared to counties with fewer economic vulnerabilities and fewer pre-existing health conditions. Declines in mobility were associated with up to 15% lower mortality rates relative to pre-social distancing levels of mobility, but effects were lagged between 25-30 days. While we cannot estimate causal impact, this study provides insight into the association of social distancing on community mortality while accounting for key community factors. For full transparency and reproducibility, we provide all data and code used in this study.One-sentence summary County-level disparities in COVID19 mortality highlight inequalities in socioeconomic and community factors and delayed effects of social distancing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementR.T. is a paid consultant of Roche.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code used for this analysis can be found or downloaded at https://github.com/phcanalytics/covid19_epi_model.